Ensartinib hydrochloride NEW
| Price | $60 | $85 | $147 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Ensartinib hydrochloride | CAS No.: 2137030-98-7 |
| Purity: 98.73% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Ensartinib hydrochloride |
| Description | Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inhibits both wild-type ALK and ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM. |
| In vitro | Ensartinib potently inhibits both wild-type ALK and all evaluated ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM. Besides ALK, ensartinib also potently inhibits GOPC-ROS1, TPM3-TRKA, and TRKC with an IC50 of <1 nM, and inhibits EphA1, EphA2, EphB1 and c-MET with an IC50 of 1-10 nM[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 33 mg/mL (52.02 mM) |
| Keywords | X 396 | X396 | Cluster of differentiation 246 | Ensartinib | Inhibitor | CD246 | X-396 | Ensartinib Hydrochloride | Anaplastic lymphoma kinase (ALK) | Anaplastic lymphoma kinase | c-Met/HGFR | ALK tyrosine kinase receptor | Ensartinib hydrochloride | X-396 Dihydrochloride | X396 Dihydrochloride | inhibit | X 396 Dihydrochloride | Ensartinib Dihydrochloride |
| Inhibitors Related | SB-431542 | DMH-1 | Larotrectinib sulfate | L-Ascorbic acid 2-phosphate trisodium | Crizotinib | Amitriptyline hydrochloride | Ceritinib | 7,8-Dihydroxyflavone | Diosmetin | GW 441756 | Cabozantinib S-malate | A 83-01 |
| Related Compound Libraries | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2380.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $0.00/1kg |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2022-10-28 | |
| $50.00/1KG |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2023-12-22 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY